The Global Ursodeoxycholic Acid Market, by Dosage Form (Solid and Liquid), by Mode of Extraction (Synthetic and Biological), by Application (Gallstones, Cystic Fibrosis, Liver Cirrhosis, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 346.2 million in 2017, and is projected to exhibit a CAGR of 7.0% over the forecast period (2018 – 2026), as highlighted in a new report published by Coherent Market Insights.
Ursodeoxycholic acid (UDCA), a secondary bile acid produced by intestinal bacteria as a metabolic by-product, has been found effective in the nonsurgical treatment of cholesterol gallstones and cystic fibrosis. Various studies conducted on UDCA have shown its application in treatment of Alzheimer’s, Parkinson’s, and other disorders. For instance, according to the University of Sheffield study, UDCA can improve mitochondrial dysfunction, which is known to be a causative factor for Alzheimer’s disease. Alzheimer’s disease is the leading cause of dementia worldwide and is the most common neurodegenerative disorder. According to the data reported by Alzheimer’s Society in 2018, Alzheimer’s is estimated to affect 225,000 by the end of 2018 in the UK and the number is expected to increase to two million by 2051. Another study conducted by Sheffield Institute for Translational Neuroscience (SITraN) in 2015, showed that UDCA can be an effective treatment in halting the progression of Parkinson’s disease.
Browse 22 Market Data Tables and 25 Figures spread through 157 Pages and in-depth TOC on “Ursodeoxycholic Acid Market, by Dosage Form (Solid and Liquid), by Mode of Extraction (Synthetic and Biological), by Application (Gallstones, Cystic Fibrosis, Liver Cirrhosis, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Global Forecast to 2026”
To know the latest trends and insights related to ursodeoxycholic acid market, click the link below:
Manufacturers in ursodeoxycholic acid market are focused on the development of products for other liver diseases such as cirrhosis. In 2016, Retrophin, Inc. received rights to market a liquid formulation of UDCA for the treatment of a rare liver disease called primary biliary cholangitis. Primary biliary cholangitis (or primary biliary cirrhosis), is a chronic liver disease that results from progressive destruction of the bile ducts in the liver. Previously, this bile acid was prescribed only in solid forms such as a tablets or capsules.
Key Takeaways of the Ursodeoxycholic Acid Market:
- The global ursodeoxycholic acid market is expected to expand at a CAGR of 7.0% during the forecast period (2018–2026), owing to increasing prevalence of liver diseases and rising research studies conducted over ursodeoxycholic acid application. According to The Johns Hopkins University 2017 information, nearly 31,000 people die each year from cirrhosis in the U.S.
- Among dosage form, solid dosage segment is expected to generate major revenue share, owing to increasing number of products available in this form.
- Major players operating in the global ursodeoxycholic acid market include, Abil Chempharma, Arcelor Chemicals, Biotavia Labs, Daewoong Chemical, Dipharma Francis, Erregierre, Grindeks, ICE, Mitsubishi Tanabe, Pharma Zell, Suzhou Tianlu, and Zhangshanbelling.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave,
Seattle, WA 98154